First Trust Advisors LP Has $46.38 Million Stock Position in argenx SE (NASDAQ:ARGX)

First Trust Advisors LP decreased its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 8.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,409 shares of the company's stock after selling 6,677 shares during the period. First Trust Advisors LP owned 0.12% of argenx worth $46,377,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. GeoWealth Management LLC grew its position in argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after purchasing an additional 18 shares during the last quarter. Whipplewood Advisors LLC bought a new stake in shares of argenx in the fourth quarter valued at about $37,000. Global Retirement Partners LLC grew its position in argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after buying an additional 48 shares in the last quarter. FIL Ltd bought a new position in argenx during the fourth quarter valued at about $38,000. Finally, Jones Financial Companies Lllp increased its stake in argenx by 1,016.7% during the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after acquiring an additional 61 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Stock Up 2.4 %

ARGX traded up $14.25 during trading on Friday, hitting $614.76. The company had a trading volume of 215,836 shares, compared to its average volume of 308,133. The company has a market capitalization of $37.54 billion, a PE ratio of -698.59 and a beta of 0.60. argenx SE has a one year low of $352.77 and a one year high of $678.21. The firm's 50-day moving average price is $598.28 and its 200 day moving average price is $608.44.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. Sell-side analysts forecast that argenx SE will post 3.13 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. William Blair reaffirmed an "outperform" rating on shares of argenx in a report on Friday, February 28th. Guggenheim raised their price target on shares of argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Wells Fargo & Company lifted their price objective on argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Piper Sandler increased their target price on argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a report on Tuesday, January 7th. Finally, JMP Securities raised their target price on argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a research report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, argenx currently has an average rating of "Moderate Buy" and an average target price of $699.28.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.